SG11202011349PA - Activatable interleukin-2 polypeptides and methods of use thereof - Google Patents

Activatable interleukin-2 polypeptides and methods of use thereof

Info

Publication number
SG11202011349PA
SG11202011349PA SG11202011349PA SG11202011349PA SG11202011349PA SG 11202011349P A SG11202011349P A SG 11202011349PA SG 11202011349P A SG11202011349P A SG 11202011349PA SG 11202011349P A SG11202011349P A SG 11202011349PA SG 11202011349P A SG11202011349P A SG 11202011349PA
Authority
SG
Singapore
Prior art keywords
polypeptides
methods
activatable interleukin
activatable
interleukin
Prior art date
Application number
SG11202011349PA
Inventor
William Winston
Daniel Hicklin
Vinay Bhaskar
Luke Evnin
Patrick Baeuerle
Garcia Jose Andres Salmeron
Heather Brodkin
Shuoyen Jack Lin
Holger Wesche
Cynthia Seidel-Dugan
Original Assignee
Werewolf Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werewolf Therapeutics Inc filed Critical Werewolf Therapeutics Inc
Publication of SG11202011349PA publication Critical patent/SG11202011349PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202011349PA 2018-05-14 2019-05-14 Activatable interleukin-2 polypeptides and methods of use thereof SG11202011349PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671225P 2018-05-14 2018-05-14
US201862756504P 2018-11-06 2018-11-06
US201862756507P 2018-11-06 2018-11-06
PCT/US2019/032321 WO2019222295A1 (en) 2018-05-14 2019-05-14 Activatable interleukin-2 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202011349PA true SG11202011349PA (en) 2020-12-30

Family

ID=66794101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011349PA SG11202011349PA (en) 2018-05-14 2019-05-14 Activatable interleukin-2 polypeptides and methods of use thereof

Country Status (14)

Country Link
US (5) US10696724B2 (en)
EP (2) EP3794024B1 (en)
JP (2) JP7460609B2 (en)
KR (1) KR20210021467A (en)
CN (1) CN113840832A (en)
AU (2) AU2019271148B2 (en)
BR (1) BR112020023160A2 (en)
CA (1) CA3100007A1 (en)
DK (1) DK3794024T3 (en)
ES (1) ES2955511T3 (en)
FI (1) FI3794024T3 (en)
MX (1) MX2020012251A (en)
SG (1) SG11202011349PA (en)
WO (1) WO2019222295A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008727A2 (en) 2016-11-28 2019-07-16 Chugai Pharmaceutical Co Ltd antigen binding domain, and polypeptide including transport section
JP7460609B2 (en) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド Activable interleukin-2 polypeptides and methods of use thereof
AU2019271149B2 (en) * 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN112654633A (en) 2018-06-22 2021-04-13 科优基因公司 Cytokine-based bioactivatable agents and methods of use thereof
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
MX2021013766A (en) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Separation moieties and methods and use thereof.
EP3983432A1 (en) 2019-06-12 2022-04-20 Askgene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
EP4004026A4 (en) * 2019-07-25 2023-11-15 Trutino Biosciences Inc. Il-2 cytokine prodrugs comprising a cleavable linker
CN115175926A (en) * 2019-11-14 2022-10-11 狼人治疗公司 Activatable cytokine polypeptides and methods of use thereof
CN110950967B (en) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 Anti-human serum albumin nano antibody and IL-2 fusion protein and preparation method thereof
JP2023510115A (en) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド NOVEL IL2 AGONISTS AND METHODS OF USING THEM
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Biased il2 muteins methods and compositions
WO2021146455A1 (en) * 2020-01-15 2021-07-22 Trutino Biosciences Inc. Cytokine il-2 prodrugs comprising a cleavable linker
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Pharmaceutical Co Ltd Ligand-binding fusion proteins
CN115698063A (en) * 2020-03-06 2023-02-03 匹兹堡大学联邦高等教育系统 Serum albumin binding nanobody compositions and methods of use thereof
MX2022011893A (en) * 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Novel immunoactive interleukin 2 analog.
WO2021202675A1 (en) * 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-2 cytokines and their cleavage products
BR112022020440A2 (en) 2020-04-10 2022-12-27 Cytomx Therapeutics Inc ACTIVATIVE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
KR20230010251A (en) * 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. Compositions of protein complexes and methods of use thereof
CN113912734A (en) * 2020-07-08 2022-01-11 南京师范大学 Fusion polypeptides and uses thereof
WO2022125583A1 (en) * 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
MX2023007326A (en) * 2020-12-18 2023-08-22 Cullinan Amber Corp Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof.
BR112023018735A2 (en) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc MASKED ACTIVABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
WO2023004368A1 (en) * 2021-07-21 2023-01-26 Trutino Biosciences Inc. Linker polypeptides
TW202334186A (en) * 2021-10-13 2023-09-01 美商Ｃｙｔｏｍｘ生物製藥公司 Trimeric activatable cytokine constructs and related compositions and methods
WO2023144412A1 (en) * 2022-01-31 2023-08-03 Aarhus Universitet A biopharmaceutical prodrug platform based on protein conformational change
CN115141283A (en) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 Fusion protein, preparation method and application thereof
WO2023220597A1 (en) * 2022-05-10 2023-11-16 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
CN117683140A (en) * 2022-09-09 2024-03-12 北京昌平实验室 Tumor-targeted fusion protein type prodrug taking interleukin 2 as active ingredient
WO2024068705A1 (en) * 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
KR20240055222A (en) * 2022-10-19 2024-04-29 주식회사 에이프릴바이오 Fusion protein comprising Interleukin-2 protein and antigen binding fragment to serum albumin, and uses thereof
CN117917438A (en) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 Antibody fusion proteins, their preparation and use

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
ES2171392T3 (en) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan PROTEIN POLYGANDS UNITED TO A STABLE PROTEIN NUCLEUS.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0669836T3 (en) 1992-11-13 1996-10-14 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19701141C1 (en) * 1997-01-16 1998-04-09 Hoechst Ag Gene construct for treatment of disease involving protease, particularly tumours and inflammation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
PT994903E (en) 1997-06-24 2005-10-31 Genentech Inc METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2532910T3 (en) 1998-04-02 2015-04-01 Genentech, Inc. Antibody variants and fragments thereof
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2568899T3 (en) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
IT1306736B1 (en) 1999-10-29 2001-10-02 Benito Salmi CONTAINMENT AND DISTRIBUTION DEVICE FOR BALLS FOR ALVOLO SHOOTS.
ES2274823T3 (en) 1999-12-29 2007-06-01 Immunogen, Inc. COTOTOXIC AGENTS THAT INCLUDE DOXORRUBICINAS AND DAUNORRUBICINAS AND ITS THERAPEUTIC USE.
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
DE10045592A1 (en) 2000-09-15 2002-03-28 Klaus Pfizenmaier An antibody-TNF-TNF inhibitor fusion protein (TNF selectokine) as a target-specific procytokine for tumor therapy
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
GB0100551D0 (en) 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CN100423777C (en) 2001-10-25 2008-10-08 杰南技术公司 Glycoprotein compositions
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
JPWO2003084569A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Antibody composition-containing medicine
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
RU2005114526A (en) 2002-10-14 2005-10-10 Ф.Хоффманн-Ля Рош Аг (Ch) ANTAGONISTS IL-15
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004060300A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP2007527695A (en) 2003-04-09 2007-10-04 アステリオン・リミテッド Polypeptides containing glycosylphosphatidylinositol
EP1631406B1 (en) 2003-06-14 2007-04-11 Stopinc Aktiengesellschaft Casting system, especially for die casting a metal melt
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CN1735264A (en) 2004-08-10 2006-02-15 皇家飞利浦电子股份有限公司 Method and device for point-to-point opposite communication
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006110728A2 (en) 2005-04-12 2006-10-19 The Uab Research Foundation Immunogenic cmv tegument aggregates
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2007294805A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
ATE554859T1 (en) 2007-05-24 2012-05-15 Univ California INTEGRATED FLUIDIC DEVICES WITH MAGNETIC SORTING
EP3492488A1 (en) * 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
EP2288386A1 (en) 2008-02-19 2011-03-02 Asterion Limited Modified linkers
US8575102B2 (en) 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
CN102482347B (en) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 Modified antibody compositions, and methods of making and using thereof
CN102481341B (en) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 Proproteins and methods of use thereof
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
CA2777222A1 (en) 2009-10-10 2011-04-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
EP2629788A4 (en) 2010-10-22 2014-03-19 Protox Therapeutics Corp Use of human serum albumin to decrease antigenicity of therapeutic proteins
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
KR20230148396A (en) 2010-11-12 2023-10-24 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
SG11201406943XA (en) 2012-04-27 2014-12-30 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013171897A1 (en) 2012-05-18 2013-11-21 太平工業株式会社 Separating mechanism for separating circular blade and/or spacer, handling robot, storage stand, and separating method
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
IN2014MN02635A (en) 2012-06-22 2015-10-16 Cytomx Therapeutics Inc
JP6445434B2 (en) 2012-08-09 2018-12-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Superkine and synthekine: recycled cytokines with novel and enhanced signaling activity
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
EP2941643A4 (en) 2013-01-04 2016-09-28 Cytomx Therapeutics Inc Compositions and methods for detecting protease activity in biological systems
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014139468A1 (en) * 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
AU2014324884B2 (en) 2013-09-25 2020-03-26 Cytomx Therapeutics, Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
DK3628328T3 (en) 2014-01-31 2022-12-05 Cytomx Therapeutics Inc MATRIPTASE AND U PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE PARTS AND METHODS OF USING THEREOF
EP3834838A1 (en) 2014-02-21 2021-06-16 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP6621478B2 (en) * 2014-12-19 2019-12-18 アルカーメス，インコーポレイテッド Single chain Fc fusion protein
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
CN107207603A (en) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 Chemotactic factor (CF) immunoglobulin fused polypeptide, its composition, preparation method and purposes
MX2017011644A (en) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
BR112017023868A2 (en) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
SG10201913767VA (en) 2015-05-04 2020-03-30 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
EP4029880A1 (en) 2015-05-04 2022-07-20 CytomX Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
MX2017014908A (en) 2015-05-21 2018-08-15 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use.
WO2016200645A1 (en) 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
JP7195927B2 (en) 2016-03-08 2022-12-26 武田薬品工業株式会社 Inducible binding proteins and methods of use thereof
KR102530742B1 (en) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. single domain serum albumin binding protein
CN107759694B (en) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
BR112019008223A2 (en) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company activatable anti-ctla-4 antibodies and uses thereof
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3589303A4 (en) 2017-03-01 2020-11-25 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
KR20190134654A (en) 2017-03-09 2019-12-04 싸이톰스 테라퓨틱스, 인크. CD147 antibody, activatable CD147 antibody, and how to make and use it
CN107082812B (en) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 It is a kind of restore debilitating immune cell function fusion protein and its application
CN110582300A (en) 2017-05-02 2019-12-17 尼克塔治疗公司 Immunotherapeutic treatment of tumors
WO2018204717A1 (en) 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
US20200078467A1 (en) 2017-05-15 2020-03-12 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
JP2020528878A (en) 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Interferon prodrug for cancer treatment
EA202090247A1 (en) 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. ANTIBODIES AGAINST CD166 AND THEIR APPLICATION
AU2018304711A1 (en) 2017-07-20 2020-01-16 Cytomx Therapeutics, Inc. Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
WO2019036031A2 (en) 2017-08-17 2019-02-21 Nektar Therapeutics Immunotherapeutic tumor treatment method
US20190117789A1 (en) 2017-08-30 2019-04-25 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
SG11202002384VA (en) 2017-10-14 2020-04-29 Cytomx Therapeutics Inc Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019094396A1 (en) 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CU24554B1 (en) 2018-05-07 2021-11-04 Ct Inmunologia Molecular FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON
JP7460609B2 (en) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド Activable interleukin-2 polypeptides and methods of use thereof
AU2019271149B2 (en) 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN112654633A (en) 2018-06-22 2021-04-13 科优基因公司 Cytokine-based bioactivatable agents and methods of use thereof
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
EP3983432A1 (en) 2019-06-12 2022-04-20 Askgene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. Il-2 cytokine prodrugs comprising a cleavable linker
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
WO2021202675A1 (en) 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-2 cytokines and their cleavage products
CN115867568A (en) 2020-04-01 2023-03-28 西里欧发展公司 Masked IL-15 cytokines and cleavage products thereof
CA3172641A1 (en) 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-12 cytokines and their cleavage products

Also Published As

Publication number Publication date
CN113840832A (en) 2021-12-24
CA3100007A1 (en) 2019-11-21
AU2019271148A1 (en) 2020-12-24
US11352403B2 (en) 2022-06-07
EP4242238A2 (en) 2023-09-13
US10696724B2 (en) 2020-06-30
JP7460609B2 (en) 2024-04-02
ES2955511T3 (en) 2023-12-04
WO2019222295A1 (en) 2019-11-21
US20230374093A1 (en) 2023-11-23
DK3794024T3 (en) 2023-08-14
JP2023178480A (en) 2023-12-14
FI3794024T3 (en) 2023-08-10
US20200283490A1 (en) 2020-09-10
EP3794024B1 (en) 2023-05-10
US11981716B2 (en) 2024-05-14
KR20210021467A (en) 2021-02-26
AU2019271148B2 (en) 2023-07-06
EP3794024A1 (en) 2021-03-24
EP4242238A3 (en) 2023-12-06
US11535658B2 (en) 2022-12-27
JP2021524757A (en) 2021-09-16
US20220056096A1 (en) 2022-02-24
US20200040052A1 (en) 2020-02-06
AU2023219887A1 (en) 2023-09-14
BR112020023160A2 (en) 2021-02-02
US20210403524A1 (en) 2021-12-30
MX2020012251A (en) 2021-04-28

Similar Documents

Publication Publication Date Title
SG11202011349PA (en) Activatable interleukin-2 polypeptides and methods of use thereof
SG11202011308VA (en) Activatable cytokine polypeptides and methods of use thereof
GB2595606B (en) CRISPR-Cas effector polypeptides and methods of use thereof
IL272332A (en) Antigen-presenting polypeptides and methods of use thereof
IL292871A (en) Activatable cytokine polypeptides and methods of use thereof
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL259514A (en) Conditionally active heterodimeric polypeptides and methods of use thereof
IL275944B (en) 2/interleukin-2 receptor alpha fusion proteins and methods of use
IL272703A (en) Activatable anti-cd166 antibodies and methods of use thereof
IL277288A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
KR102201086B9 (en) Il-2 cd80 fusion protein comprising il-2 protein and cd80 protein and use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
IL282856A (en) Activatable anti-cd166 antibodies and methods of use thereof
SG10201913699QA (en) Glucagon-receptor selective polypeptides and methods of use thereof
EP3810185A4 (en) Interleukin-2 variants and methods of uses thereof
IL262727A (en) Cd40l-fc fusion polypeptides and methods of use thereof
IL280102A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL280922A (en) Anti-her2 polypeptides and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL280103A (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL280808A (en) Ox40-binding polypeptides and uses thereof
EP4081533A4 (en) Crispr-cas effector polypeptides and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof